Cited by 54Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchMenopause: Health Impacts and Treatments

Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease

Open access
Oveisgharan, Shahram, Yang, Jingyun, Yu, Lei, Burba, Dominika, Bang, Woojeong, Tasaki, Shinya, Grodstein, Fran, Wang, Yanling +4 more·2023·Neurology

Abstract

Background and Objectives Lifetime risk of Alzheimer disease (AD) dementia is twofold higher in women compared with men, and low estrogen levels in postmenopause have been suggested as a possible contributor. We examined 3 ER (GPER1, ER2, and ER1) variants in association with AD traits as an indirect method to test the association between estrogen and AD in women. Although the study focus was on women, in a comparison, we separately examined ER molecular variants in men. Methods Participants were followed for an average of 10 years in one of the 2 longitudinal clinical pathologic studies of aging. Global cognition was assessed using a composite score derived from 19 neuropsychological tests9 scores. Postmortem pathologic assessment included examination of 3 AD (amyloid-β and tau tangles determined by immunohistochemistry, and a global AD pathology score derived from diffuse and neurotic plaques and neurofibrillary tangle count) and 8 non-AD pathology indices. ER molecular genomic variants included genotyping and examining ER DNA methylation and RNA expression in brain regions including the dorsolateral prefrontal cortex (DLPFC) that are major players in cognition and often have AD pathology. Results The mean age of women (N = 1711) at baseline was 78.0 (SD = 7.7) years. In women, GPER1 molecular variants had the most consistent associations with AD traits. GPER1 DNA methylation was associated with cognitive decline, tau tangle density, and global AD pathology score. GPER1 RNA expression in DLPFC was related to cognitive decline and tau tangle density. Other associations included associations of ER2 and ER1 sequence variants and DNA methylation with cognition. RNA expressions in DLPFC of genes involved in signaling mechanisms of activated ERs were also associated with cognitive decline and tau tangle density in women. In men (N = 651, average age at baseline: 77.4 [SD = 7.3]), there were less robust associations between ER molecular genomic variants and AD cognitive and pathologic traits. No consistent association was seen between ER molecular genomic variations and non-AD pathologies in either of the sexes. Discussion ER DNA methylation and RNA expression, and to some extent ER polymorphisms, were associated with AD cognitive and pathologic traits in women, and to a lesser extent in men.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000206833

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Transcriptome-wide sex differences in AD have been characterized in multiple studies.

    “While transcriptome‐wide sex differences in AD have been characterized in multiple studies, 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 proteome‐wide sex differences in AD remain underexplored.”

    From Unraveling sex differences in Alzheimer's disease and related endophenotypes with brain proteomes (2025) · cites this paper as [16]

    The RNA Expression Processing section describes transcriptome-scale sequencing, and the Discussion reports different associations between estrogen-receptor molecular variants and AD traits in women and men. But the analyses focus on selected estrogen-receptor genes and their pathways; this paper does not characterize transcriptome-wide sex differences in AD. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Estrogen receptor expression has stronger associations with AD cognitive and pathologic traits in females than males.

    “Expression of the estrogen receptor had stronger associations with AD cognitive and pathologic traits in females than males.”
  • Our results corroborate previous studies that highlighted a sex-specific association between AD and estrogen receptors.

    “Our results corroborate previous studies that highlighted a sex‐specific association between AD and estrogen receptors. 15 , 16”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Oveisgharan, S., Yang, J., Yu, L., Burba, D., Bang, W., Tasaki, S., Grodstein, F., Wang, Y., Zhao, J., De Jager, P. L., Schneider, J. A., & Bennett, D. A.
Affiliations
  • Rush University Medical Center (US)
  • From the Rush Alzheimer's Disease Center (S.O., J.Y., L.Y., D.B., W.B., S.T., F.G., Y.W., J.A.S., D.A.B.), Rush University Medical Center, Chicago; Departments of Neurological Sciences (S.O., J.Y., L.Y., S.T., J.A.S., D.A.B.) and Internal Medicine (F.G.), Rush University Medical Center, Chicago, IL; Department of Epidemiology (J.Z.), University of Florida, Gainesville; Center for Translational & Computational Neuroimmunology (P.L.D.J.), Department of Neurology, Columbia University Irving Medical...
Venue
Neurology
Published
2023-04-04
Volume
100
Issue
14
Pages
e1474-e1487
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W4318016632
Cited by
53
References
49
Citations by year
2026: 10 · 2025: 20 · 2024: 16 · 2023: 7
FWCI
9.41
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Aging (R01AG017917, U01AG046152, R01AG015819, P30AG010161, R01AG064786, P30AG072975)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords
estrogen receptor gene, Alzheimer's disease, cognitive decline, G protein-coupled estrogen receptor, estrogen receptor 2, estrogen receptor 1, DNA methylation, gene expression, dorsolateral prefrontal cortex, tau tangles, amyloid plaques, sex differences, postmenopausal estrogen, genetic variants
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Male, Receptors, Estrogen, RNA, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review